Eli Lilly (NYSE: LLY) to Announce Q4 2025 Financial Results on February 4, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy LLY?
Source: Newsfilter
- Earnings Announcement: Eli Lilly is set to release its fourth-quarter 2025 financial results on February 4, 2026, which is expected to provide investors with critical financial data to assess the company's performance.
- Conference Call Details: On the same day, Lilly will conduct a conference call at 10 a.m. Eastern Time to elaborate on its financial performance, enhancing communication with investors and the media.
- Live Webcast Access: Investors and the general public can access the live webcast of the conference call through a link on Lilly's website, ensuring transparency and broadening audience reach to enhance the company's image.
- Commitment to Diversity: Lilly is dedicated to reflecting global diversity through innovative clinical trials, advancing drug development to tackle significant health challenges worldwide, thereby reinforcing its leadership position in the pharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1192 USD with a low forecast of 950.00 USD and a high forecast of 1500 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1003.460
Low
950.00
Averages
1192
High
1500
Current: 1003.460
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Strong Q4 Results, Raises 2026 Revenue Guidance
- Significant Revenue Growth: Eli Lilly's Q4 revenue reached $19.3 billion, a 43% increase year-over-year, surpassing analyst expectations of $17.86 billion, indicating sustained momentum in its obesity and diabetes product portfolio.
- Earnings Per Share Increase: Q4 earnings rose by 51% to $7.39 per share, exceeding market expectations of $7.22, reflecting a notable improvement in the company's profitability.
- Optimistic Future Outlook: Eli Lilly expects revenue for fiscal 2026 to be between $80 billion and $83 billion, significantly higher than fiscal 2025, demonstrating the company's confidence in future growth.
- Annual Performance Review: For the full year, Eli Lilly's total revenue grew by 45% to $65.18 billion, showcasing its strong performance and competitiveness in the market.
See More
Eli Lilly Reports Strong Q4 2025 Financial Results and 2026 Guidance
- Significant Revenue Growth: In Q4 2025, Eli Lilly achieved global revenue of $19.29 billion, a 43% increase year-over-year, primarily driven by a 46% rise in volume, indicating strong market performance and sustained product demand.
- Substantial Net Income Increase: The net income for Q4 reached $6.64 billion, up 50% from $4.41 billion in Q4 2024, demonstrating the company's effective cost control and market expansion, which bolsters investor confidence.
- Increased R&D Investment: R&D expenses rose 26% to $3.8 billion in Q4 2025, representing 20% of revenue, reflecting the company's ongoing commitment to drug development aimed at enhancing future product innovation and market competitiveness.
- 2026 Financial Outlook: Eli Lilly projects revenue for 2026 to be between $80 billion and $83 billion, showcasing confidence in future growth while planning to maintain a tax rate between 18% and 19%, indicating a robust financial management strategy.
See More
US Stocks Close Mixed: Nasdaq Hits Seven-Week Low
- Chipmaker Sell-off: Advanced Micro Devices (AMD) plunged over 17% after analysts issued a weak Q1 sales forecast, raising concerns about AI demand and pressuring the broader tech sector, particularly high-flying stocks.
- Super Micro Computer Surge: Super Micro Computer's stock rose more than 13% after forecasting Q3 net sales of at least $12.3 billion, significantly above the consensus estimate of $10.25 billion, indicating strong growth potential in a competitive market.
- Mixed Economic Data: The January ADP employment change rose by 22,000, falling short of the expected 45,000, while the ISM services index remained unchanged at 53.8, exceeding expectations, reflecting the complexities of economic recovery that may influence future monetary policy.
- Improved Market Sentiment: Market sentiment improved following President Trump's signing of a government funding deal, although the agreement only funds the Department of Homeland Security through February 13, highlighting ongoing uncertainties in government operations.
See More
Wall Street Volatility Highlights Importance of Portfolio Diversification
- Tech Stock Decline: Tech stocks have been severely impacted by recent volatility, with AMD's share price plummeting 17% as investor confidence in the enterprise software sector wanes, highlighting the risks of over-reliance on tech investments.
- Strong Performance of Blue-Chip Stocks: In stark contrast to tech stocks, the Dow Jones Industrial Average rose by 260 points, or 0.5%, indicating that old-economy companies are demonstrating greater resilience during market turmoil, attracting investors seeking stability.
- Winners Across Industries: Companies like Campbell, PepsiCo, Smuckers, and Kraft Heinz have seen their stock prices rise despite the threat of GLP-1, reflecting ongoing consumer demand and confidence in the food sector amidst market fluctuations.
- Recovery in Banks and Industrials: Recent gains in bank stocks and industrials such as Honeywell, Dover, and Emerson Electric suggest that investors believe these firms will benefit from efficiency improvements brought by artificial intelligence, enhancing their investment appeal.
See More
Diverging Market Outlooks for Eli Lilly and Novo Nordisk
- Sales Outlook Divergence: Eli Lilly forecasts 2026 sales between $80 billion and $83 billion, exceeding analyst expectations of $77.62 billion, with a projected 25% growth, highlighting its strong position in the obesity and diabetes drug market.
- Novo Nordisk's Challenges: In contrast, Novo Nordisk warns of a 5% to 13% decline in sales and profits due to falling prices in the U.S. and patent expirations in China, Brazil, and Canada, indicating pressure on its market share.
- Drug Competitive Advantage: Lilly's tirzepatide is superior in effectiveness and tolerability compared to Novo's semaglutide, and Lilly is actively driving global uptake, which is expected to further solidify its market leadership.
- Medicare Coverage Expansion: Lilly anticipates that Medicare coverage starting in July will open access for 40 million new beneficiaries to obesity treatments, potentially significantly increasing prescription volumes and driving sales growth.
See More
Diverging 2026 Outlooks for Novo Nordisk and Eli Lilly
- Intensifying Market Competition: Novo Nordisk anticipates a sales decline of 5% to 13% for 2026, while Eli Lilly forecasts a 25% increase in sales, reaching $80 billion to $83 billion, highlighting the intensifying competitive landscape in the obesity drug market.
- Differential Drug Efficacy: Lilly's tirzepatide is considered superior in effectiveness and tolerability compared to Novo's semaglutide, with clinical trial results indicating a preference among prescribers, which will further drive Lilly's market share growth.
- Expanded Medicare Coverage: Lilly expects government Medicare to cover obesity treatments for the first time by July 2023, potentially opening access to 40 million new beneficiaries, significantly expanding market potential and increasing prescription volumes.
- Patent Protection Advantage: While Novo faces challenges from expiring patents in some international markets, Lilly's tirzepatide is expected to be protected into the late 2030s in major markets, providing a safeguard for future sales growth.
See More
Eli Lilly Reports Strong Q4 Results, Raises 2026 Revenue Guidance
- Significant Revenue Growth: Eli Lilly's Q4 revenue reached $19.3 billion, a 43% increase year-over-year, surpassing analyst expectations of $17.86 billion, indicating sustained momentum in its obesity and diabetes product portfolio.
- Earnings Per Share Increase: Q4 earnings rose by 51% to $7.39 per share, exceeding market expectations of $7.22, reflecting a notable improvement in the company's profitability.
- Optimistic Future Outlook: Eli Lilly expects revenue for fiscal 2026 to be between $80 billion and $83 billion, significantly higher than fiscal 2025, demonstrating the company's confidence in future growth.
- Annual Performance Review: For the full year, Eli Lilly's total revenue grew by 45% to $65.18 billion, showcasing its strong performance and competitiveness in the market.
See More
Eli Lilly Reports Strong Q4 2025 Financial Results and 2026 Guidance
- Significant Revenue Growth: In Q4 2025, Eli Lilly achieved global revenue of $19.29 billion, a 43% increase year-over-year, primarily driven by a 46% rise in volume, indicating strong market performance and sustained product demand.
- Substantial Net Income Increase: The net income for Q4 reached $6.64 billion, up 50% from $4.41 billion in Q4 2024, demonstrating the company's effective cost control and market expansion, which bolsters investor confidence.
- Increased R&D Investment: R&D expenses rose 26% to $3.8 billion in Q4 2025, representing 20% of revenue, reflecting the company's ongoing commitment to drug development aimed at enhancing future product innovation and market competitiveness.
- 2026 Financial Outlook: Eli Lilly projects revenue for 2026 to be between $80 billion and $83 billion, showcasing confidence in future growth while planning to maintain a tax rate between 18% and 19%, indicating a robust financial management strategy.
See More
US Stocks Close Mixed: Nasdaq Hits Seven-Week Low
- Chipmaker Sell-off: Advanced Micro Devices (AMD) plunged over 17% after analysts issued a weak Q1 sales forecast, raising concerns about AI demand and pressuring the broader tech sector, particularly high-flying stocks.
- Super Micro Computer Surge: Super Micro Computer's stock rose more than 13% after forecasting Q3 net sales of at least $12.3 billion, significantly above the consensus estimate of $10.25 billion, indicating strong growth potential in a competitive market.
- Mixed Economic Data: The January ADP employment change rose by 22,000, falling short of the expected 45,000, while the ISM services index remained unchanged at 53.8, exceeding expectations, reflecting the complexities of economic recovery that may influence future monetary policy.
- Improved Market Sentiment: Market sentiment improved following President Trump's signing of a government funding deal, although the agreement only funds the Department of Homeland Security through February 13, highlighting ongoing uncertainties in government operations.
See More
Wall Street Volatility Highlights Importance of Portfolio Diversification
- Tech Stock Decline: Tech stocks have been severely impacted by recent volatility, with AMD's share price plummeting 17% as investor confidence in the enterprise software sector wanes, highlighting the risks of over-reliance on tech investments.
- Strong Performance of Blue-Chip Stocks: In stark contrast to tech stocks, the Dow Jones Industrial Average rose by 260 points, or 0.5%, indicating that old-economy companies are demonstrating greater resilience during market turmoil, attracting investors seeking stability.
- Winners Across Industries: Companies like Campbell, PepsiCo, Smuckers, and Kraft Heinz have seen their stock prices rise despite the threat of GLP-1, reflecting ongoing consumer demand and confidence in the food sector amidst market fluctuations.
- Recovery in Banks and Industrials: Recent gains in bank stocks and industrials such as Honeywell, Dover, and Emerson Electric suggest that investors believe these firms will benefit from efficiency improvements brought by artificial intelligence, enhancing their investment appeal.
See More
Diverging Market Outlooks for Eli Lilly and Novo Nordisk
- Sales Outlook Divergence: Eli Lilly forecasts 2026 sales between $80 billion and $83 billion, exceeding analyst expectations of $77.62 billion, with a projected 25% growth, highlighting its strong position in the obesity and diabetes drug market.
- Novo Nordisk's Challenges: In contrast, Novo Nordisk warns of a 5% to 13% decline in sales and profits due to falling prices in the U.S. and patent expirations in China, Brazil, and Canada, indicating pressure on its market share.
- Drug Competitive Advantage: Lilly's tirzepatide is superior in effectiveness and tolerability compared to Novo's semaglutide, and Lilly is actively driving global uptake, which is expected to further solidify its market leadership.
- Medicare Coverage Expansion: Lilly anticipates that Medicare coverage starting in July will open access for 40 million new beneficiaries to obesity treatments, potentially significantly increasing prescription volumes and driving sales growth.
See More
Diverging 2026 Outlooks for Novo Nordisk and Eli Lilly
- Intensifying Market Competition: Novo Nordisk anticipates a sales decline of 5% to 13% for 2026, while Eli Lilly forecasts a 25% increase in sales, reaching $80 billion to $83 billion, highlighting the intensifying competitive landscape in the obesity drug market.
- Differential Drug Efficacy: Lilly's tirzepatide is considered superior in effectiveness and tolerability compared to Novo's semaglutide, with clinical trial results indicating a preference among prescribers, which will further drive Lilly's market share growth.
- Expanded Medicare Coverage: Lilly expects government Medicare to cover obesity treatments for the first time by July 2023, potentially opening access to 40 million new beneficiaries, significantly expanding market potential and increasing prescription volumes.
- Patent Protection Advantage: While Novo faces challenges from expiring patents in some international markets, Lilly's tirzepatide is expected to be protected into the late 2030s in major markets, providing a safeguard for future sales growth.
See More
